Sjögren's syndrome in dermatology

Clinics in Dermatology

Volumn 24, Issue 5, 2006, Pages 393-413

  Fox, Robert I ^a   Liu, Alice Y ^a  

^a SCRIPPS MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AF 102; ANDROGEN; ANTICOAGULANT AGENT; ANTIMALARIAL AGENT; ARTIFICIAL TEAR; AZATHIOPRINE; BICARBONATE; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CEVIMELINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HISTAMINE H2 RECEPTOR ANTAGONIST; HLA DR ANTIGEN; HYPNOTIC AGENT; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PILOCARPINE; PROTON PUMP INHIBITOR; PURINERGIC RECEPTOR STIMULATING AGENT; RITUXIMAB; RO ANTIBODY; SEROTONIN UPTAKE INHIBITOR; STEROID; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBODY DETECTION; ARTHRALGIA; ARTHRITIS; ARTICLE; ATROPHIC GASTRITIS; B LYMPHOCYTE; BLEPHARITIS; CANCER RISK; CARDIOMYOPATHY; CLINICAL FEATURE; DEPRESSION; DERMATOMYOSITIS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRY EYE; ENVIRONMENTAL FACTOR; FIBROMYALGIA; HUMAN; INTERSTITIAL NEPHRITIS; INTERSTITIAL PNEUMONIA; IRITIS; KERATOCONJUNCTIVITIS SICCA; LIP BIOPSY; LYMPHADENOPATHY; LYMPHOMA; MIKULICZ DISEASE; MOUTH HYGIENE; MYALGIA; MYOSITIS; PAROTID ENLARGEMENT; PATHOGENESIS; PERICARDITIS; PERIPHERAL NEUROPATHY; PLEURISY; PRIORITY JOURNAL; PSEUDOLYMPHOMA; RAYNAUD PHENOMENON; RENAL DIABETES; RHEUMATOID ARTHRITIS; SALIVARY GLAND BIOPSY; SCLERODERMA; SJOEGREN SYNDROME; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; UVEITIS; XEROPHTHALMIA; XEROSTOMIA;

AUTOIMMUNE DISEASES; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KERATOCONJUNCTIVITIS SICCA; LUBRICATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; SJOGREN'S SYNDROME; SKIN; SKIN DISEASES; VASCULITIS; XEROSTOMIA;

EID: 33748758174     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2006.07.005     Document Type: Article

References (223)

1. Mikulicz J.H. Uber eine eigenartige symmetrische Erkrankung der Tranen- und Mundspeicheldrusen. In: Billroth G.T. (Ed). Beitr Chir Fortschr (1892) 610-630 [Stuttgart]
2. Daniels T.E., and Fox P.C. Salivary and oral components of Sjogren's syndrome. Rheum Dis Clin North Am 18 (1992) 571-589
3. Morgan W., and Castleman B. A clinicopathologic study of Mikulicz's disease. Am J Pathol 29 (1953) 471-503
4. Bloch K.J., Buchanan W.W., Wohl M.J., and Bunim J.J. Sjögren's syndrome: a clinical, pathological and serological study of 62 cases. Medicine (Baltimore) 44 (1956) 187-231
5. Bowman S.J., Ibrahim G.H., Holmes G., Hamburger J., and Ainsworth J.R. Estimating the prevalence among Caucasian women of primary Sjogren's syndrome in two general practices in Birmingham, UK. Scand J Rheumatol 33 (2004) 39-43
6. Fox R.I., Tornwall J., and Michelson P. Current issues in the diagnosis and treatment of Sjogren's syndrome. Curr Opin Rheumatol 11 (1999) 364-371
7. Pillemer S.R., Matteson E.L., Jacobsson L.T., et al. Incidence of physician-diagnosed primary Sjogren syndrome in residents of Olmsted County, Minnesota. Mayo Clin Proc 76 (2001) 593-599
8. Cimaz R., Casadei A., Rose C., et al. Primary Sjogren syndrome in the paediatric age: a multicentre survey. Eur J Pediatr 162 (2003) 661-665
9. Fox R.I., Robinson C., Curd J., Michelson P., Bone R., and Howell F.V. First international symposium on Sjögren's syndrome: suggested criteria for classification. Scand J Rheumatol 562 (1986) 28-30
10. Vitali C., Moutsopoulos H.M., and Bombardieri S. The European Community Study Group on diagnostic criteria for Sjogren's syndrome. Sensitivity and specificity of tests for ocular and oral involvement in Sjogren's syndrome. Ann Rheum Dis 53 (1994) 637-647
11. Fox R. Sjogren's syndrome: progress and controversies. Med Clin North Am 17 (1997) 434-441
12. Vitali C. Classification criteria for Sjogren's syndrome. Ann Rheum Dis 62 (2003) 94-95 [author reply 95]
13. Chan E.K.L., Sullivan K.F., Fox R.I., and Tan E.M. Sjögren's syndrome nuclear antigen B (La): cDNA cloning, structural domains, and autoepitopes. J Autoimmun 2 (1989) 321-327
14. Ben-Chetrit E., Fox R.I., and Tan E.M. Dissociation of immune responses to the SS-A (Ro) 52-kd and 60-kd polypeptides in systemic lupus erythematosus and Sjögren's syndrome. Arthritis Rheum 33 (1990) 349-355
15. Harley J.B., Alexander E.L., Bias W.B., et al. Anti-Ro (SS-A) and Anti-La (SS-B) in patients with Sjögren's syndrome. Arthritis Rheum 29 (1986) 196-206
16. Fei H.M., Kang H.-I., Scharf S., Erlich H., Peebles C., and Fox R.I. Specific HLA-DQA and HLA-DRB1 alleles confer susceptibility to Sjögren's syndrome and autoantibody SS-B production. J Clin Lab Anal 5 (1991) 382-391
17. Hamilton R.G., Harley J.B., Bias W.B., et al. Two Ro (SS-A) autoantibody responses in systemic lupus erythematous. Arthritis Rheum 31 (1988) 446-505
18. Rader M.D., O'Brien C., Liu Y., Harley J.B., and Reichlin M. Heterogeneity of the Ro/SSA antigen. J Clin Invest 83 (1989) 1293-1298
19. Gaither K.K., Fox O.W., Yamagata H., Mamula M.J., Reichlin M., and Harley J.B. Implications of anti-Ro/Sjögren's syndrome A antigen autoantibody in normal sera for autoimmunity. J Clin Invest 79 (1987) 841-846
20. Sestak A.L., Harley J.B., Yoshida S., and Reichlin M. Lupus/Sjögren's autoantibody specificities in sera with paraproteins. J Clin Invest 80 (1987) 138-144
21. Tan E.M., Feltkamp T.E., Smolen J.S., et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum 40 (1997) 1601-1611
22. Lightfoot R. Cost effective use of laboratory tests in rheumatology. Bull Rheum Dis 46 (1997) 1-3
23. Daniels Taf.., and P.C. Salivary and oral components of Sjogren's syndrome. Rheum Dis Clin North Am 18 (1992) 571-583
24. Fox R.I., and Howell F.V. Oral problems in patients with Sjögren's syndrome. Scand J Rheumatol S61 (1986) 194-200
25. Bone R.C., Fox R.I., Howell F.V., and Fantozzi R. Sjögren's syndrome: new immunologic assessments for a persistent clinical problem. Laryngoscope 95 (1985) 295-299
26. Daniels T.E. Labial salivary gland biopsy in Sjögren's syndrome. Arthritis Rheum 27 (1984) 147-156
27. Daniels T.E., and Wu A.J. Xerostomia-clinical evaluation and treatment in general practice. J Calif Dent Assoc 28 (2000) 933-941
28. Radfar L., Kleiner D.E., Fox P.C., and Pillemer S.R. Prevalence and clinical significance of lymphocytic foci in minor salivary glands of healthy volunteers. Arthritis Rheum 47 (2002) 520-524
29. Vivino F.B., Gala I., and Hermann G.A. Change in final diagnosis on second evaluation of labial minor salivary gland biopsies. J Rheumatol 29 (2002) 938-944
30. Tapinos N.I., Polihronis M., Tzioufas A.G., and Moutsopoulos H.M. Sjogren's syndrome. Autoimmune epithelitis. Adv Exp Med Biol 455 (1999) 127-134
31. Robinson C.P., Yamamoto H., Peck A.B., and Humphreys-Beher M.G. Genetically programmed development of salivary gland abnormalities in the NOD (nonobese diabetic)-scid mouse in the absence of detectable lymphocytic infiltration: a potential trigger for sialoadenitis of NOD mice. Clin Immunol Immunopathol 79 (1996) 50-59
32. Salomonsson S., Larsson P., Tengner P., Mellquist E., Hjelmstrom P., and Wahren-Herlenius M. Expression of the B cell-attracting chemokine CXCL13 in the target organ and autoantibody production in ectopic lymphoid tissue in the chronic inflammatory disease Sjogren's syndrome. Scand J Immunol 55 (2002) 336-342
33. Xanthou G., Polihronis M., Tzioufas A.G., Paikos S., Sideras P., and Moutsopoulos H.M. "Lymphoid" chemokine messenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands of Sjogren's syndrome patients: possible participation in lymphoid structure formation. Arthritis Rheum 44 (2001) 408-418
34. Ma-Krupa W., Jeon M.S., Spoerl S., Tedder T.F., Goronzy J.J., and Weyand C.M. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med 199 (2004) 173-183
35. Takeda K., Kaisho T., and Akira S. Toll-like receptors. Annu Rev Immunol 21 (2003) 335-376
36. Vaughan J.H., Nguyen M.D., Valbracht J.R., Patrick K., and Rhodes G.H. Epstein-Barr virus-induced autoimmune responses: II. Immunoglobulin G autoantibodies to mimicking and nonmimicking epitopes. Presence in autoimmune disease. J Clin Invest 95 (1995) 1316-1327
37. Li J.M., Horsfall A.C., and Maini R.N. Anti-La (SS-B) but not anti-Ro52 (SS-A) antibodies cross-react with laminin-a role in the pathogenesis of congenital heart block?. Clin Exp Immunol 99 (1995) 316-324
38. Stathopoulou E.A., Routsias J.G., Stea E.A., Moutsopoulos H.M., and Tzioufas A.G. Cross-reaction between antibodies to the major epitope of Ro60 kD autoantigen and a homologous peptide of Coxsackie virus 2B protein. Clin Exp Immunol 141 (2005) 148-154
39. Nakamura H., Kawakami A., Yamasaki S., et al. Expression and function of X chromosome-linked inhibitor of apoptosis protein in Sjogren's syndrome. Lab Invest 80 (2000) 1421-1427
40. Jonsson R., Gordon T.P., and Konttinen Y.T. Recent advances in understanding molecular mechanisms in the pathogenesis and antibody profile of Sjogren's syndrome. Curr Rheumatol Rep 5 (2003) 311-316
41. Sawalha A.H., Potts R., Schmid W.R., Scofield R.H., and Harley J.B. The genetics of primary Sjogren's syndrome. Curr Rheumatol Rep 5 (2003) 324-332
42. Scofield R.H., Kurien B.T., Zhang F., et al. Protein-protein interaction of the Ro-ribonucleoprotein particle using multiple antigenic peptides. [In Process Citation]. Mol Immunol 36 (1999) 1093-1106
43. McClain M.T., Heinlen L.D., Dennis G.J., Roebuck J., Harley J.B., and James J.A. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med 11 (2005) 85-89
44. Heinlen L.D., McClain M.T., Kim X., et al. Anti-Ro and anti-nRNP response in unaffected family members of SLE patients. Lupus 12 (2003) 335-337
45. Arbuckle M.R., McClain M.T., Rubertone M.V., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349 (2003) 1526-1533
46. Kaufman K.M., Kirby M.Y., McClain M.T., Harley J.B., and James J.A. Lupus autoantibodies recognize the product of an alternative open reading frame of SmB/B′. Biochem Biophys Res Commun 285 (2001) 1206-1212
47. Mariette X., Roux S., Zhang J., et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 62 (2003) 168-171
48. Lavie F., Miceli-Richard C., Quillard J., Roux S., Leclerc P., and Mariette X. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjogren's syndrome. J Pathol 202 (2004) 496-502
49. Santiago-Raber M.L., Baccala R., Haraldsson K.M., et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 197 (2003) 777-788
50. Ogawa N., Ping L., Zhenjun L., Takada Y., and Sugai S. Involvement of the interferon-gamma-induced T cell-attracting chemokines, interferon-gamma-inducible 10-kd protein (CXCL10) and monokine induced by interferon-gamma (CXCL9), in the salivary gland lesions of patients with Sjogren's syndrome. Arthritis Rheum 46 (2002) 2730-2741
51. Bolstad A.I., and Jonsson R. Gene therapeutics in Sjogren's syndrome. Expert Opin Biol Ther 5 (2005) 763-772
52. Hjelmervik T.O., Petersen K., Jonassen I., Jonsson R., and Bolstad A.I. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum 52 (2005) 1534-1544
53. Bolstad A.I., Eiken H.G., Rosenlund B., Alarcon-Riquelme M.E., and Jonsson R. Increased salivary gland tissue expression of Fas, Fas ligand, cytotoxic T lymphocyte-associated antigen 4, and programmed cell death 1 in primary Sjogren's syndrome. Arthritis Rheum 48 (2003) 174-185
54. Konttinen Y.T., Hukkanen M., Kemppinen P., et al. Peptide-containing nerves in labial salivary glands in Sjögren's syndrome. Arthritis Rheum 35 (1992) 815-820
55. Konttinen Y.T., and Kasna-Ronkainen L. Sjogren's syndrome: viewpoint on pathogenesis. One of the reasons I was never asked to write a textbook chapter on it. Scand J Rheumatol Suppl (2002) 15-22
56. Tsubota K., Hirai S., King L.S., Agre P., and Ishida N. Defective cellular trafficking of lacrimal gland aquaporin-5 in Sjogren's syndrome. Lancet 357 (2001) 688-689
57. Steinfeld S., Cogan E., King L.S., Agre P., Kiss R., and Delporte C. Abnormal distribution of aquaporin-5 water channel protein in salivary glands from Sjogren's syndrome patients. Lab Invest 81 (2001) 143-148
58. Stern M.E., Beuerman R.W., Fox R.I., Gao J., Mircheff A.K., and Pflugfelder S.C. A unified theory of the role of the ocular surface in dry eye. Adv Exp Med Biol 438 (1998) 643-651
59. Fox R.I., and Stern M. Sjogren's syndrome: mechanisms of pathogenesis involve interaction of immune and neurosecretory systems. Scand J Rheumatol Suppl 116 (2002) 3-13
60. Pflugfelder S.C. Differential diagnosis of dry eye conditions. Adv Dent Res 10 (1996) 9-12
61. Daniels T.E. Evaluation, differential diagnosis, and treatment of xerostomia. J Rheumatol Suppl 61 (2000) 6-10
62. Allison P.J., Locker D., and Feine J.S. The relationship between dental status and health-related quality of life in upper aerodigestive tract cancer patients. Oral Oncol 35 (1999) 138-143
63. Soto-Rojas A.E., and Kraus A. The oral side of Sjogren syndrome. Diagnosis and treatment. A review. Arch Med Res 33 (2002) 95-106
64. Beroukas D., Goodfellow R., Hiscock J., Jonsson R., Gordon T.P., and Waterman S.A. Up-regulation of M3-muscarinic receptors in labial salivary gland acini in primary Sjogren's syndrome. Lab Invest 82 (2002) 203-210
65. Fox R.I., Konttinen Y., and Fisher A. Use of muscarinic agonists in the treatment of Sjogren's syndrome. Clin Immunol 101 (2001) 249-263
66. Fisher A., Heldman E., Gurwitz D., et al. M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update. Ann N Y Acad Sci 777 (1996) 189-196
67. Bergdahl J., and Bergdahl M. Environmental illness: evaluation of salivary flow, symptoms, diseases, medications, and psychological factors. Acta Odontol Scand 59 (2001) 104-110
68. Yousem D.M., Kraut M.A., and Chalian A.A. Major salivary gland imaging. Radiology 216 (2000) 19-29
69. Tonami H., Higashi K., Matoba M., Yokota H., Yamamoto I., and Sugai S. A comparative study between MR sialography and salivary gland scintigraphy in the diagnosis of Sjogren syndrome. J Comput Assist Tomogr 25 (2001) 262-268
70. Salaffi F., Argalia G., Carotti M., Giannini F.B., and Palombi C. Salivary gland ultrasonography in the evaluation of primary Sjogren's syndrome. Comparison with minor salivary gland biopsy. J Rheumatol 27 (2000) 1229-1236
71. Belafsky P.C., and Postma G.N. The laryngeal and esophageal manifestations of Sjogren's syndrome. Curr Rheumatol Rep 5 (2003) 297-303
72. Alexander E.L., and Provost T.T. Cutaneous manifestations of primary Sjögren's syndrome: a reflection of vasculitis and association with anti-Ro (SSA) antibodies. J Invest Dermatol 80 (1983) 386-391
73. Ito Y., Kanda N., Mitsui H., et al. Cutaneous manifestations of Sjogren's syndrome associated with myasthenia gravis. [letter]. Br J Dermatol 141 (1999) 362-363
74. Sais G., Admella C., Fantova M.J., and Montero J.C. Lymphocytic autoimmune hidradenitis, cutaneous leucocytoclastic vasculitis and primary Sjogren's syndrome. Br J Dermatol 139 (1998) 1073-1076
75. Gemignani F., Marbini A., Pavesi G., et al. Peripheral neuropathy associated with primary Sjogren's syndrome. J Neurol Neurosurg Psychiatry 57 (1994) 983-986
76. Hebbar M., Lassalle P., Janin A., et al. E-Selectin expression in salivary endothelial cells and sera from patients with systemic sclerosis. Role of resident mast cell-derived tumor necrosis factor alpha. Arthritis Rheum 38 (1995) 406-412
77. Cho C.S., Park S.H., Min J.K., Lee S.H., and Kim H.Y. Clinical significances of antibodies to Ro/SS-A autoantigens and its subtypes in primary Sjogren's syndrome. Korean J Intern Med 12 (1997) 176-181
78. Kyle R., Gleich G., Bayrid E., and Vaughn J.H. Benign hyperglobulinemic purpura of Waldenstrom. Medicine (Baltimore) 50 (1971) 113-123
79. Fox R.I., Carson D.A., Chen P., and Fong S. Characterization of a cross reactive idiotype in Sjögren's syndrome. Scand J Rheumatol 561 (1986) 83-88
80. Fox R.I., Chen P.P., Carson D.A., and Fong S. Expression of a cross reactive idiotype on rheumatoid factor in patients with Sjögren's syndrome. J Immunol 136 (1986) 477-483
81. Fox R.I., Fong S., Chen P.P., and Kipps T.J. Autoantibody production in Sjögren's syndrome: a hypothesis regarding defects in somatic diversification of germ line encoded genes. In Vivo 2 (1988) 47-56
82. Fong S., Chen P.P., Fox R.I., et al. The diversity and idiotypic pattern of human rheumatoid factors in disease. Concepts Immunopathol 5 (1988) 168-191
83. Ramos-Casals M., Cervera R., Yague J., et al. Cryoglobulinemia in primary Sjogren's syndrome: prevalence and clinical characteristics in a series of 115 patients. Semin Arthritis Rheum 28 (1998) 200-205
84. Bernacchi E., Amato L., Parodi A., et al. Sjogren's syndrome: a retrospective review of the cutaneous features of 93 patients by the Italian Group of Immunodermatology. Clin Exp Rheumatol 22 (2004) 55-62
85. Alexander E., and Provost T.T. Sjögren's syndrome. Association of cutaneous vasculitis with central nervous system disease. Arch Dermatol 123 (1987) 801-810
86. Provost T.T., Watson R., and Simmons O.B.E. Anti-Ro(SS-A) antibody positive Sjogren's/lupus erythematosus overlap syndrome. Lupus 6 (1997) 105-111
87. Konishi M., Ohosone Y., Matsumura M., et al. Mixed-cryoglobulinemia associated with cutaneous vasculitis and pulmonary symptoms. Intern Med 36 (1997) 62-67
88. Ferri C., La Civita L., Longombardo G., Zignego A.L., and Pasero G. Mixed cryoglobulinaemia: a cross-road between autoimmune and lymphoproliferative disorders. Lupus 7 (1998) 275-279
89. Ferri C., Bernini L., Cecchetti R., et al. Cutaneous and serologic subsets of systemic sclerosis. J Rheumatol 18 (1991) 1826-1832
90. O'Donnell B., and Black A.K. Urticarial vasculitis. Int Angiol 14 (1995) 166-174
91. Provost T.T., Watson R., and Simmons-O'Brien E. Anti-Ro(SS-A) antibody positive Sjogren's/lupus erythematosus overlap syndrome. Lupus 6 (1997) 105-111
92. Provost T.T., and Watson R. Cutaneous manifestations of Sjogren's syndrome. Rheum Dis Clin North Am 18 (1992) 609-616
93. Merkel P.A., Polisson R.P., Chang Y., Skates S.J., and Niles J.L. Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med 126 (1997) 866-873
94. Merkel P.A., Chang Y., Pierangeli S.S., Convery K., Harris E.N., and Polisson R.P. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am J Med 101 (1996) 576-583
95. Navarro M., Cervera R., Font J., et al. Anti-endothelial cell antibodies in systemic autoimmune diseases: prevalence and clinical significance. Lupus 6 (1997) 521-526
96. Asherson R.A., Fei H.M., Staub H.L., Khamashta M.A., Hughes G.R.V., and Fox R.I. Antiphospholipid antibodies and HLA associations in primary Sjögren's syndrome. Ann Rheum Dis 51 (1992) 495-498
97. Roguedas A.M., Misery L., Sassolas B., Le Masson G., Pennec Y.L., and Youinou P. Cutaneous manifestations of primary Sjogren's syndrome are underestimated. Clin Exp Rheumatol 22 (2004) 632-636
98. Jubert C., Cosnes A., Clerici T., et al. Sjogren's syndrome and cutaneous B cell lymphoma revealed by anetoderma. Arthritis Rheum 36 (1993) 133-134
99. Pablos J.L., Cogolludo V., Pinedo F., and Carreira P.E. Subcutaneous nodular amyloidosis in Sjögren's syndrome. Scand J Rheumatol 22 (1993) 250-251
100. Yoneyama K., Tochigi N., Oikawa A., Shinkai H., and Utani A. Primary localized cutaneous nodular amyloidosis in a patient with Sjogren's syndrome: a review of the literature. J Dermatol 32 (2005) 120-123
101. Yamamoto T., Katayama I., and Nishioka K. Analysis of T cell receptor Vbeta repertoires of annular erythema associated with Sjogren's syndrome. Eur J Dermatol 8 (1998) 248-251
102. Ramos-Casals M., Anaya J.M., Garcia-Carrasco M., et al. Cutaneous vasculitis in primary Sjogren syndrome: classification and clinical significance of 52 patients. Medicine (Baltimore) 83 (2004) 96-106
103. Foster E.N., Nguyen K.K., Sheikh R.A., and Prindiville T.P. Crohn's disease associated with Sweet's syndrome and Sjogren's syndrome treated with infliximab. Clin Dev Immunol 12 (2005) 145-149
104. Pirildar T., Tikiz C., Ozkaya S., et al. Endothelial dysfunction in patients with primary Sjogren's syndrome. Rheumatol Int 25 (2005) 536-539
105. Manoussakis M.N., Georgopoulou C., Zintzaras E., et al. Sjogren's syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjogren's syndrome. Arthritis Rheum 50 (2004) 882-891
106. Tektonidou M., Kaskani E., Skopouli F.N., and Moutsopoulos H.M. Microvascular abnormalities in Sjogren's syndrome: nailfold capillaroscopy. Rheumatology (Oxford) 38 (1999) 826-830
107. Gyulai R., Kiss M., Mehravaran M., et al. Atypical autoimmune blistering dermatosis associated with Sjogren's syndrome. Acta Derm Venereol 82 (2002) 462-464
108. Ruzicka T., Faes J., Bergner T., Peter R.U., and Braun-Falco O. Annular erythema associated with Sjogren's syndrome: a variant of systemic lupus erythematosus. J Am Acad Dermatol 25 (1991) 557-560
109. Mori K., Iijima M., Koike H., et al. The wide spectrum of clinical manifestations in Sjogren's syndrome-associated neuropathy. Brain 128 (2005) 2518-2534
110. Watanabe T., Tsuchida T., Furue M., and Yoshinoya S. Annular erythema, dermatomyositis, and Sjogren's syndrome. Int J Dermatol 35 (1996) 285-287
111. Watanabe T., Tsuchida T., Ito Y., Kanda N., Ueda Y., and Tamaki K. Annular erythema associated with lupus erythematosus/Sjogren's syndrome. J Am Acad Dermatol 36 2 Pt 1 (1997) 214-218
112. Katayama Y., and Kohriyama K. Telomerase activity in peripheral blood mononuclear cells of systemic connective tissue diseases. J Rheumatol 28 (2001) 288-291
113. Katayama I., Yamamoto T., Otoyama K., Matsunaga T., and Nishioka K. Clinical and immunological analysis of annular erythema associated with Sjogren syndrome. Dermatology 189 Suppl 1 (1994) 14-17
114. Miyagawa S., Iida T., Fukumoto T., Matsunaga T., Yoshioka A., and Shirai T. Anti-Ro/SSA-associated annular erythema in childhood. Br J Dermatol 133 (1995) 779-782
115. Haimowitz J.E., McCauliffe D.P., Seykora J., and Werth V.P. Annular erythema of Sjogren's syndrome in a white woman. J Am Acad Dermatol 42 (2000) 1069-1072
116. Pease C.T., Shattles W., Barrett N.K., and Maini R.N. The arthropathy of Sjogren's syndrome. Br J Rheumatol 32 (1993) 609-613
117. Fox R.I. Sjogren's syndrome: current therapies remain inadequate for a common disease. Expert Opin Investig Drugs 9 (2000) 2007-2016
118. Lindvall B., Bengtsson A., Ernerudh J., and Eriksson P. Subclinical myositis is common in primary Sjogren's syndrome and is not related to muscle pain. J Rheumatol 29 (2002) 717-725
119. Bonafede R.P., Downey D.C., and Bennett R.M. An association of fibromyalgia with primary Sjogren's syndrome: a prospective study of 72 patients. J Rheumatol 22 (1995) 133-136
120. Quismorio Jr. F.P. Pulmonary involvement in primary Sjogren's syndrome. Curr Opin Pulm Med 2 (1996) 424-428
121. Battista G., Zompatori M., Poletti V., and Canini R. Thoracic manifestations of the less common collagen diseases. A pictorial essay. Radiol Med (Torino) 106 (2003) 445-451 [quiz 452-3]
122. Constantopoulos S.H., Tsianos E.V., and Moutsopoulos H.M. Pulmonary and gastrointestinal manifestations of Sjogren's syndrome. Rheum Dis Clin North Am 18 (1992) 617-635
123. Kim E.A., Lee K.S., Johkoh T., et al. Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings. Radiographics 22 Spec No (2002) S151-S165
124. Chatterjee S. Severe interstitial pneumonitis associated with infliximab therapy. Scand J Rheumatol 33 (2004) 276-277
125. Swords R., Power D., Fay M., O'Donnell R., and Murphy P.T. Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP). Am J Hematol 77 (2004) 103-104
126. Gyongyosi M., Pokorny G., Jambrik Z., et al. Cardiac manifestations in primary Sjogren's syndrome. Ann Rheum Dis 55 (1996) 450-454
127. Andonopoulos A.P., Christodoulou J., Ballas C., Bounas A., and Alexopoulos D. Autonomic cardiovascular neuropathy in Sjogren's syndrome. A controlled study. J Rheumatol 25 (1998) 2385-2388
128. Press J., Uziel Y., Laxer R.M., Luy L., Hamilton R.M., and Silverman E.D. Long-term outcome of mothers of children with complete congenital heart block. Am J Med 100 (1996) 328-332
129. Borda E., Leiros C.P., Bacman S., Berra A., and Sterin-Borda L. Sjogren autoantibodies modify neonatal cardiac function via M1 muscarinic acetylcholine receptor activation. Int J Cardiol 70 (1999) 23-32
130. Gamron S., Barberis G., Onetti C.M., et al. Mesangial nephropathy in Sjogren's syndrome. Scand J Rheumatol 29 (2000) 65-67
131. Siamopoulos K.C., Elisaf M., and Moutsopoulos H.M. Hypokalaemic paralysis as the presenting manifestation of primary Sjogren's syndrome. Nephrol Dial Transplant 9 (1994) 1176-1178
132. Fulop M., and Mackay M. Renal tubular acidosis, Sjogren syndrome, and bone disease. Arch Intern Med 164 (2004) 905-909
133. Nishimagi E., Kawaguchi Y., Terai C., Kajiyama H., Hara M., and Kamatani N. Progressive interstitial renal fibrosis due to Chinese herbs in a patient with calcinosis Raynaud esophageal sclerodactyly telangiectasia (CREST) syndrome. Intern Med 40 (2001) 1059-1063
134. Dabadghao S., Aggarwal A., Arora P., Pandey R., and Misra R. Glomerulonephritis leading to end stage renal disease in a patient with primary Sjogren syndrome. Clin Exp Rheumatol 13 (1995) 509-511
135. Leppilahti M., Tammela T.L., Huhtala H., Kiilholma P., Leppilahti K., and Auvinen A. Interstitial cystitis-like urinary symptoms among patients with Sjogren's syndrome: a population-based study in Finland. Am J Med 115 (2003) 62-65
136. Shibata S., Ubara Y., Sawa N., et al. Severe interstitial cystitis associated with Sjogren's syndrome. Intern Med 43 (2004) 248-252
137. Beroukas D., Hiscock J., Jonsson R., Waterman S.A., and Gordon T.P. Subcellular distribution of aquaporin 5 in salivary glands in primary Sjogren's syndrome. Lancet 358 (2001) 1875-1876
138. Feist E., Kuckelkorn U., Dorner T., et al. Autoantibodies in primary Sjogren's syndrome are directed against proteasomal subunits of the alpha and beta type. Arthritis Rheum 42 (1999) 697-702
139. Collin P., Karvonen A.L., Korpela M., Laippala P., and Helin H. Gastritis classified in accordance with the Sydney system in patients with primary Sjogren's syndrome. Scand J Gastroenterol 32 (1997) 108-111
140. Raderer M., Osterreicher C., Machold K., et al. Impaired response of gastric MALT-lymphoma to Helicobacter pylori eradication in patients with autoimmune disease. Ann Oncol 12 (2001) 937-939
141. Invernizzi P., Battezzati P.M., Crosignani A., et al. Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status. Clin Exp Immunol 114 (1998) 448-454
142. Tishler M., Alosachie I., Barka N., et al. Primary Sjogren's syndrome and primary biliary cirrhosis: differences and similarities in the autoantibody profile. Clin Exp Rheumatol 13 (1995) 497-500
143. Zukowski T.H., Jorgensen R.A., Dickson E.R., and Lindor K.D. Autoimmune conditions associated with primary biliary cirrhosis: response to ursodeoxycholic acid therapy. Am J Gastroenterol 93 (1998) 958-961
144. Sheikh S.H., and Shaw-Stiffel T.A. The gastrointestinal manifestations of Sjogren's syndrome. Am J Gastroenterol 90 (1995) 9-14
145. Collin P., Reunala T., Rasmussen M., et al. High incidence and prevalence of adult coeliac disease. Augmented diagnostic approach. Scand J Gastroenterol 32 (1997) 1129-1133
146. D'Arbonneau F., Ansart S., Le Berre R., Dueymes M., Youinou P., and Pennec Y.L. Thyroid dysfunction in primary Sjogren's syndrome: a long-term follow-up study. Arthritis Rheum 49 (2003) 804-809
147. Perez B., Kraus A., Lopez G., Cifuentes M., and Alarcon-Segovia D. Autoimmune thyroid disease in primary Sjogren's syndrome. Am J Med 99 (1995) 480-484
148. Tektonidou M.G., Anapliotou M., Vlachoyiannopoulos P., and Moutsopoulos H.M. Presence of systemic autoimmune disorders in patients with autoimmune thyroid diseases. Ann Rheum Dis 63 (2004) 1159-1161
149. Nishimori I., Okazaki K., Yamamoto Y., Morita M., Tamura S., and Yamamoto Y. Specific cellular immune responses to pancreatic antigen in chronic pancreatitis and Sjögren's syndrome. J Clin Immunol 13 (1993) 265-271
150. Johnson E.O., Vlachoyiannopoulos P.G., Skopouli F.N., Tzioufas A.G., and Moutsopoulos H.M. Hypofunction of the stress axis in Sjogren's syndrome. J Rheumatol 25 (1998) 1508-1514
151. Kassan S.S., Thomas T.L., Moutsopoulos H.M., et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 89 (1978) 888-892
152. Voulgarelis M., Dafni U.G., Isenberg D.A., and Moutsopoulos H.M. Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's Syndrome. Arthritis Rheum 42 (1999) 1765-1772
153. Royer B., Cazals-Hatem D., Sibilia J., et al. Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood 90 (1997) 766-775
154. Nishimura M., Miyajima S., and Okada N. Salivary gland MALT lymphoma associated with Helicobacter pylori infection in a patient with Sjogren's syndrome. [In Process Citation]. J Dermatol 27 (2000) 450-452
155. Josephs S.F., Buchbinder A., Streicher H.Z., et al. Detection of human B-lymphotropic virus (human herpesvirus 6) sequences in B-cell lymphoma tissues of three patients. Leukemia 2 (1988) 132-135
156. Nakamura H., Kawakami A., Tominaga M., et al. Relationship between Sjogren's syndrome and human T-lymphotropic virus type I infection: follow-up study of 83 patients [In Process Citation]. J Lab Clin Med 135 (2000) 139-144
157. Kamel O.W., van de Rijn M., Weiss L.M., et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 328 (1993) 1317-1321
158. Delalande S., de Seze J., Fauchais A.L., et al. Neurologic manifestations in primary Sjogren syndrome: a study of 82 patients. Medicine (Baltimore) 83 (2004) 280-291
159. Urban P.P., Keilmann A., Teichmann E.M., and Hopf H.C. Sensory neuropathy of the trigeminal, glossopharyngeal, and vagal nerves in Sjogren's syndrome. J Neurol Sci 186 (2001) 59-63
160. Barendregt P.J., van Den Bent M.J., van Raaij-Van Den Aarssen V.J., et al. Involvement of the peripheral nervous system in primary Sjogren's syndrome. Ann Rheum Dis 60 (2001) 876-881
161. Grant I.A., Hunder G.G., Homburger H.A., and Dyck P.J. Peripheral neuropathy associated with sicca complex. Neurology 48 (1997) 855-862
162. Rosler D.H., Conway M.D., Anaya J.M., et al. Ischemic optic neuropathy and high-level anticardiolipin antibodies in primary Sjogren's syndrome. Lupus 4 (1995) 155-157
163. Alexander E.L., Malinow K., Lejewski J.E., Jerdan M.S., Provost T.T., and Alexander G.E. Primary Sjögren's syndrome with central nervous system disease mimicking multiple sclerosis. Ann Intern Med 104 (1986) 323-330
164. Simmons-O'Brien E., Chen S., Watson R., et al. One hundred anti-Ro (SS-A) antibody positive patients: a 10-year follow-up. Medicine (Baltimore) 74 (1995) 109-130
165. Pender M.P. Recent progress in the diagnosis and treatment of multiple sclerosis. J Clin Neurosci 6 (1999) 367-372
166. de Seze J., Devos D., Castelnovo G., et al. The prevalence of Sjogren syndrome in patients with primary progressive multiple sclerosis. Neurology 57 (2001) 1359-1363
167. Fisher A. Muscarinic receptor agonists in Alzheimer's disease. CNS Drugs 12 (1999) 197-214
168. Utset T.O., Golden M., Siberry G., Kiri N., Crum R.M., and Petri M. Depressive symptoms in patients with systemic lupus erythematosus: association with central nervous system lupus and Sjogren's syndrome. J Rheumatol 21 (1994) 2039-2045
169. van Dam A.P., Wekking E.M., Callewaert J.A., et al. Psychiatric symptoms before systemic lupus erythematosus is diagnosed. Rheumatol Int 14 (1994) 57-62
170. Lass P., Krajka-Lauer J., Homziuk M., et al. Cerebral blood flow in Sjogren's syndrome using 99Tcm-HMPAO brain SPET. Nucl Med Commun 21 (2000) 31-35
171. Belin C., Moroni C., Caillat-Vigneron N., et al. Central nervous system involvement in Sjogren's syndrome: evidence from neuropsychological testing and HMPAO-SPECT [In Process Citation]. Ann Med Interne (Paris) 150 (1999) 598-604
172. Spezialetti R., Bluestein H.G., Peter J.B., and Alexander E.L. Neuropsychiatric disease in Sjogren's syndrome: anti-ribosomal P and anti-neuronal antibodies. Am J Med 95 (1993) 153-160
173. Tensing E.K., Solovieva S.A., Tervahartiala T., et al. Fatigue and health profile in sicca syndrome of Sjogren's and non-Sjogren's syndrome origin. Clin Exp Rheumatol 19 (2001) 313-316
174. Lwin C.T., Bishay M., Platts R.G., Booth D.A., and Bowman S.J. The assessment of fatigue in primary Sjogren's syndrome. Scand J Rheumatol 32 (2003) 33-37
175. Tishler M., Barak Y., Paran D., and Yaron M. Sleep disturbances, fibromyalgia and primary Sjogren's syndrome. Clin Exp Rheumatol 15 (1997) 71-74
176. Hamano T. Lacrimal duct occlusion for the treatment of dry eye. Semin Ophthalmol 20 (2005) 71-74
177. Musadiq M., Mukherji S., and Sandramouli S. Pyogenic granuloma following silicone punctal plugs: report of two cases. Orbit 24 (2005) 149-151
178. Kim B.M., Osmanovic S.S., and Edward D.P. Pyogenic granulomas after silicone punctal plugs: a clinical and histopathologic study. Am J Ophthalmol 139 (2005) 678-684
179. Tatlipinar S., and Akpek E.K. Topical ciclosporin in the treatment of ocular surface disorders. Br J Ophthalmol 89 (2005) 1363-1367
180. Berdoulay A., English R.V., and Nadelstein B. Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca. Vet Ophthalmol 8 (2005) 225-232
181. Aragona P., Stilo A., Ferreri F., and Mobrici M. Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sjogren's syndrome patients. Eye 19 (2005) 535-539
182. Papas AS, Joshi A, MacDonald SL, Maravelis-Splagounias L, Pretara-Spanedda P, Curro FA. Caries prevalence in xerostomic individuals. J Can Dent Assoc 1993;59: 171-4, 177-9.
183. Papas A.S., Joshi A., Belanger A.J., Kent Jr. R.L., Palmer C.A., and DePaola P.F. Dietary models for root caries. Am J Clin Nutr 61 (1995) 417S-422S
184. Papas A.S., Joshi A., Palmer C.A., Giunta J.L., and Dwyer J.T. Relationship of diet to root caries. Am J Clin Nutr 61 (1995) 423S-429S
185. Suzuki K., Matsumoto M., Nakashima M., et al. Effect of cevimeline on salivary components in patients with Sjogren syndrome. Pharmacology 74 (2005) 100-105
186. Christensen L.B., Petersen P.E., Thorn J.J., and Schiodt M. Dental caries and dental health behavior of patients with primary Sjogren syndrome. Acta Odontol Scand 59 (2001) 116-120
187. Schiodt M., Christensen L.B., Petersen P.E., and Thorn J.J. Periodontal disease in primary Sjogren's syndrome. Oral Dis 7 (2001) 106-108
188. Isidor F., Brondum K., Hansen H.J., Jensen J., and Sindet-Pedersen S. Outcome of treatment with implant-retained dental prostheses in patients with Sjogren syndrome. Int J Oral Maxillofac Implants 14 (1999) 736-743
189. Robinson C., Yamciuka S., Alford C., et al. Elevated levels of cysteine protease activity in saliva and salivary glands of NOD mouse model for Sjogren's syndrome. Proc Natl Acad Sci U S A 94 (1997) 5767-5771
190. Yamamoto H., Ishibashi K., Nakagawa Y., et al. Detection of alterations in the levels of neuropeptides and salivary gland responses in the non-obese diabetic mouse model for autoimmune sialoadenitis. Scand J Immunol 45 (1997) 55-61
191. Wu A.J., and Fox P.C. Sjogren's syndrome. Semin Dermatol 13 (1994) 138-143
192. Wu A.J. The oral component of Sjogren's syndrome: pass the scalpel and check the water. Curr Rheumatol Rep 5 (2003) 304-310
193. Hay K.D., and Morton R.P. The efficacy of casein phosphoprotein-calcium phosphate complex (DC-CP) [Dentacal] as a mouth moistener in patients with severe xerostomia. N Z Dent J 99 (2003) 46-48
194. Hay K.D., and Thomson W.M. A clinical trial of the anticaries efficacy of casein derivatives complexed with calcium phosphate in patients with salivary gland dysfunction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 93 (2002) 271-275
195. Pers J.O., d'Arbonneau F., Devauchelle-Pensec V., Saraux A., Pennec Y.L., and Youinou P. Is periodontal disease mediated by salivary BAFF in Sjogren's syndrome?. Arthritis Rheum 52 (2005) 2411-2414
196. Pers J.O., Daridon C., Devauchelle V., et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 1050 (2005) 34-39
197. Castillo J.L., and Milgrom P. Fluoride release from varnishes in two in vitro protocols. J Am Dent Assoc 135 (2004) 1696-1699
198. Castillo J.L., Milgrom P., Kharasch E., Izutsu K., and Fey M. Evaluation of fluoride release from commercially available fluoride varnishes. J Am Dent Assoc 132 (2001) 1389-1392 [quiz 1459-1460]
199. Banting D.W., Papas A., Clark D.C., Proskin H.M., Schultz M., and Perry R. The effectiveness of 10% chlorhexidine varnish treatment on dental caries incidence in adults with dry mouth. Gerodontology 17 (2000) 67-76
200. Papas A.S., Fernandez M.M., Castano R.A., Gallagher S.C., Trivedi M., and Shrotriya R.C. Oral pilocarpine for symptomatic relief of dry mouth and dry eyes in patients with Sjogren's syndrome. Adv Exp Med Biol 438 (1998) 973-978
201. Katelaris C.H. Pilocarpine for dry mouth and dry eye in Sjogren's syndrome. Curr Allergy Asthma Rep 5 (2005) 321
202. Wall G.C., Magarity M.L., and Jundt J.W. Pharmacotherapy of xerostomia in primary Sjogren's syndrome. Pharmacotherapy 22 (2002) 621-629
203. Petrone D., Condemi J.J., Fife R., Gluck O., Cohen S., and Dalgin P. A double-blind, randomized, placebo-controlled study of cevimeline in Sjogren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 46 (2002) 748-754
204. Fox R.I., Chan E., Benton L., Fong S., Friedlaender M., and Howell F.V. Treatment of primary Sjögren's syndrome with hydroxychloroquine. Am J Med 85 (1988) 62-67
205. Fox R.I., Dixon R., Guarrasi V., and Krubel S. Treatment of primary Sjogren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 5 Suppl 1 (1996) S31-S36
206. Wallace D. Antimalarial agents and lupus. Rheum Dis Clin North Am 20 (1994) 243-263
207. Kruize A., Hene R., Kallenberg C., et al. Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial. Ann Rheum Dis 52 (1993) 360-364
208. Bernstein H.N. Ocular safety of hydroxychloroquine. Ann Ophthalmol 23 (1991) 292-296
209. Deheinzelin D., Capelozzi V.L., Kairalla R.A., Barbas Filho J.V., Saldiva P.H., and de Carvalho C.R. Interstitial lung disease in primary Sjogren's syndrome. Clinical-pathological evaluation and response to treatment [see comments]. Am J Respir Crit Care Med 154 3 Pt 1 (1996) 794-799
210. Skopouli F.N., Jagiello P., Tsifetaki N., and Moutsopoulos H.M. Methotrexate in primary Sjogren's syndrome. Clin Exp Rheumatol 14 (1996) 555-558
211. Price E.J., Rigby S.P., Clancy U., and Venables P.J. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjogren's syndrome. J Rheumatol 25 (1998) 896-899
212. Wallace D.J. Management of lupus erythematosus: recent insights. Curr Opin Rheumatol 14 (2002) 212-219
213. Dalavanga Y.A., Detrick B., Hooks J.J., Drosos A.A., and Moutsopoulos H.M. Effect of cyclosporin A (CyA) on the immunopathological lesion of the minor salivary glands from patients with Sjögren's syndrome. Ann Rheum Dis 46 (1990) 89-92
214. Gross W.L. New concepts in treatment protocols for severe systemic vasculitis. Curr Opin Rheumatol 11 (1999) 41-46
215. Steinfeld S.D., Demols P., Salmon I., Kiss R., and Appelboom T. Infliximab in patients with primary Sjogren's syndrome: a pilot study. Arthritis Rheum 44 (2001) 2371-2375
216. Marriette X. Lack of benefit of infliximab in Sjogren's syndrome. Arthritis Rhem (2003) [abstract S19]
217. Zandbelt M.M., de Wilde P., van Damme P., Hoyng C.B., van de Putte L., and van den Hoogen F. Etanercept in the treatment of patients with primary Sjogren's syndrome: a pilot study. J Rheumatol 31 (2004) 96-101
218. Sankar V., Brennan M.T., Kok M.R., et al. Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 50 (2004) 2240-2245
219. Cohen Y., Polliack A., and Nagler A. Treatment of refractory autoimmune diseases with ablative immunotherapy using monoclonal antibodies and/or high dose chemotherapy with hematopoietic stem cell support. Curr Pharm Des 9 (2003) 279-288
220. Bowman S.J. Collaborative research into outcome measures in Sjogren's syndrome. Update on disease assessment. Scand J Rheumatol Suppl (2002) 23-27
221. Illei G.G., Tackey E., Lapteva L., and Lipsky P.E. Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum 50 (2004) 2048-2065
222. Buyon J.P. Neonatal lupus. Curr Opin Rheumatol 8 (1996) 485-490
223. Kassan S.S., and Moutsopoulos H.M. Clinical manifestations and early diagnosis of Sjogren syndrome. Arch Intern Med 164 (2004) 1275-1284